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Objective: The goals of this study were to determine if endothelial nitric oxide synthase (eNOS) affects both early and late
collateral arterial adaptation and blood flow recovery after severe limb ischemia in a mouse model and to determine if
eNOS-derived NO is necessary for recruitment of chemokine (C-X-C motif) receptor 4 (CXCR4) vascular endothelial
growth factor receptor-1 (VEGFR1) hemangiocytes to the site of ischemia.
Methods: Two studies were completed. In the first, hind limb ischemia was induced by unilateral femoral artery excision
in three groups: C57Bl6 (wild-type), eNOS/, and C57Bl/6 mice treated with NG-nitro-L-arginine methyl ester
(L-NAME) from 1 day before excision through day 3 after excision (early L-NAME group). These groups were studied
on day 3 after induction of ischemia. In the second study, hind limb ischemia was induced in C57Bl/6 mice (wild-type)
and C57Bl/6mice treated with L-NAME from days 3 through 28 after induction of ischemia. These groups were studied
day 28 after ischemia induction. Dependent variables included hind limb perfusion, collateral artery diameter, and the
number and location of hemangiocytes within the ischemic hind limb.
Results: In the first study, toe gangrene developed in the eNOS/ and early L-NAME treatment groups by day 2. These
groups demonstrated less blood flow recovery and smaller collateral artery diameter than the wild-type group.
Hemangiocytes were present within the adventitia of collateral arteries in the wild-type group but were only sparsely
present, in a random pattern, in the eNOS/ and early L-NAME treatment groups. In the second study, the late
L-NAME group showed less blood flow recovery and smaller collateral artery diameter on day 28 of ischemia than the
wild-type group.Hemangiocytes were present in a pericapillary distribution in the wild-type group, but were present only
sparsely in the late L-NAME treatment group.
Conclusion:Early (day 3) and late (day 28) adaptive responses to hind limb ischemia both require eNOS–derivedNO.NO
is necessary for normal hemangiocyte recruitment to the ischemic tissue. (J Vasc Surg 2010;51:165-73.)
Clinical Relevance: This study demonstrates that endothelial nitric oxide synthase (eNOS)-derived NO is requisite for both
the early and late vascular recovery phases in response to hind limb ischemia. Moreover, it demonstrates that recruitment of
hemangiocytes, a specific subset of vascular progenitor cells that display vascular endothelial growth factor receptor 1
(VEGFR1) and chemokine (C-X-C motif) receptor 4 (CXCR4) surface antigens, is dependent on the presence of NO. These
findings enhance understanding of the basic biologic mechanisms in the recovery from ischemia. The need for eNOS-derived
NO suggests that clinical strategies to enhance postocclusive flow recovery in peripheral artery diseasemight bemore successful
if eNOS or NO, or both, are applied as a part of the treatment paradigm. Hemangiocytes are an important part of the cellular
response to ischemia. The present findings underscore their importance and suggest that preservation or enhancement of
eNOS within the ischemic limb might improve the recruitment of these critical reparative cells to the site of ischemic injury.Critical limb ischemia secondary to peripheral arterial
disease is a debilitating and potentially lethal disease. Crit-
ical limb ischemia is responsible for 150,000 amputa-
tions each year in the United States.1 In many patients,
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are not possible, and amputations are necessary. For these
reasons, the development of molecular or cell-based therapies
to enhance collateral artery enlargement and angiogenesis
continues to be an area of substantial scientific and clinical
interest.
Enlargement of the diameter of existing collateral arteries
is themeans bywhich blood flowdownstream from the site of
conduit artery occlusion is restored.2,3 At least three mecha-
nisms participate in this process: shear stress,4,5 inflamma-
tion,6 and recruitment of bone marrow-derived vascular pro-
genitor cells to areas of ischemia.7-10 Nitric oxide (NO) is a
component in each of these mechanisms.11-14
During the early adaptive response to ischemia, in-
creased shear stress within collateral arteries leads to NO-
induced vasodilation that results in a transient, temporary
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adaptive response to ischemia, NO participates in the re-
cruitment of vascular progenitor cells that generate collat-
eral artery remodeling, a process termed arteriogenesis,
wherein net conductance across the collateral vessels is
permanently increased.12-14
It is not universally accepted that NO derived from the
endothelial isoform of nitric oxide synthase (eNOS) is
requisite for arteriogenesis.11 In addition, the involvement
of NO in the recruitment of hemangiocytes, a critically
important subset of vascular progenitor cells,10,15 has not
been defined. This study was designed to determine if
eNOS-derived NO is essential for both the early and late
adaptive response to ischemia—to arteriogenesis—and to
determine the importance of NO in hemangiocyte recruit-
ment. We hypothesized that (1) eNOS-derived NO pro-
duction is essential for collateral artery remodeling, or
arteriogenesis, during the late adaptive response to isch-
emia and (2) recruitment of bone marrow-derived heman-
giocytes to the ischemic hind limb vasculature requires the
presence of eNOS-derived NO.
MATERIALS AND METHODS
Experimental animals and procedures. The care of
mice used in this study complied with the National Re-
search Council’s Guide for the Care and the Use of Labora-
tory Animals. All protocols were approved by the Institu-
tional Animal Care andUse Committee at the University of
Massachusetts (Worcester, Mass).
C57Bl/6 mice and eNOS/ mice (Jackson Labora-
tories, Bar Harbor, Me) were fed standard chow and main-
tained on a 12-hour light/dark cycle. Hind limb ischemia
was generated by ligation of the femoral artery at the
inguinal ligament and popliteal fossa, followed by excision
of the artery and all branches.16 The procedure was done
under 3% isoflurane anesthesia. Buprenorphine was admin-
istered during the immediate postoperative period.
Experimental protocols. The early and late adaptive
responses to acute hind limb ischemia were evaluated in
separate studies. The early adaptive response to ischemia
(vasodilation) was studied 3 days after unilateral femoral
artery excision in three groups: C57Bl/6 mice (wild-type
group), mice with targeted disruption of the eNOS loci
(eNOS/ group), and C57Bl/6 mice treated with NG-
nitro-L-arginine methyl ester (L-NAME; 1 g/L) added to
the drinking water 24 hours before femoral artery excision
(early L-NAME group). The L-NAME treatment was con-
tinued until sacrifice on day 3 after induction of ischemia, a
time selected because preliminary work indicated that mice
in the eNOS/ and early L-NAME groups uniformly
developed limb gangrene by this time.
The late adaptive response to ischemia (arteriogenesis)
was studied 28 days after induction of ischemia in two
groups: C57Bl/6 mice (wild-type group) and C57Bl/6
mice treated with L-NAME (1 g/L in drinking water)
beginning on day 3 after the induction of hind limb isch-
emia (late L-NAME group). The L-NAME treatment was
continued until sacrifice. Day 28 after induction of hindlimb ischemia was chosen as the time for study in the late
adaptive response experiment because published reports
indicate that postischemia arteriogenesis is evident at that
time.3 The late adaptive response to ischemia was not
studied in eNOS/mice because significant autoamputa-
tion consistently developed in these animals consistently by
day 3 after induction of ischemia and we did not believe it
was ethically appropriate to keep them alive 3 days.
Laser Doppler perfusion imaging. A laser Doppler
perfusion imager (LDPI; Moor Instruments Ltd, Devon,
United Kingdom) was used to estimate blood flow within
calf muscles. LDPI-derived data strongly correlate with calf
muscle blood flow measured directly using microspheres,
and the method is widely used to quantify perfusion in the
rodent hind limb.16
Hair from limbs was removed by depilatory cream, and
mice were placed on a heating plate at 37°C to minimize
temperature variation. Studies were conducted under 1.5%
isoflurane anesthesia. Data are presented as the ratio of
perfusion to the ischemic hind limb and the contralateral
nonischemic hind limb.
Immunostaining of thigh collateral arteries. The
thighmuscles were harvested on day 3 or 28 after induction
of ischemia in the early or late adaptive response groups,
respectively. Collateral arteries were identified by double
staining with antibodies for CD31 (platelet endothelial cell
adhesion molecule-1, a marker of endothelial cells) and
smooth muscle actin (both antibodies from BD Bio-
sciences, San Jose, Calif). Collateral artery diameter was
measured in 10 randomly selected low-power fields using
precalibrated microscope calipers (Carl Zeiss, Göttingen,
Germany), and the average diameter for the ischemic and
contralateral nonischemic hind limb was determined for
each mouse. Collateral arterial diameter was expressed as a
ratio of the diameters in ischemic and nonischemic hind
limbs. All measurements were made in a blinded manner.
Immunostaining for hemangiocytes. The presence
of hemangiocytes was measured in thigh muscles on day 3
or 28 after the induction of ischemia in the early and late
adaptive response groups, respectively. Hemangiocytes
were identified by double staining for chemokine (C-X-C
motif) receptor 4 (CXCR4) and vascular endothelial
growth factor receptor 1 (VEGFR1; both antibodies from
BD Bioscience).10 The number of hemangiocytes was de-
termined in 10 randomly selected high-power fields in
ischemic and contralateral and nonischemic thigh muscle,
and the average was calculated. Observations were made in
a blinded manner.
Confocal microscopy. ALeica DM IRBE confocal mi-
croscope was used (Leica Microsystems, Wetzler, Germany).
Cy3-conjugated CXCR4 and fluorescein isothiocyanate-
conjugated VEGFR1 antibodies (BD Bioscience) were
used to identify hemangiocytes. Nuclei were identified by
Draq5 staining (Biostatus Limited, Leicestershire, United
Kingdom).
Nitrate/nitrite assay. Serum samples were processed
using a nitrate/nitrite (NOx) fluorometric assay kit (Cay-
man Chemical, Ann Arbor, Mich), which determines the
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– and NO3
–, the final products gen-
erated during NO metabolism in vivo. Fluorescence was
detected using a Biotek Synergy 2 detector (BioTek Instru-
ments Inc, Winooski, Vt).
Statistical analysis. Differences among groups at each
time point were analyzed by analysis of variance (ANOVA)
for comparisons between three groups of mice, and the t
test for comparisons between two groups, where appropri-
ate. If the ANOVA f statistic was significant (P .05), then
post hoc Student-Newman-Keuls tests were done to deter-
mine the sites of significance at the P .05 level threshold.
RESULTS
Early adaptive response to hind limb ischemia. The
serumNOx concentration in the eNOS
/ group was 67%
less than that noted in the wild-type group. Treatment of
C57Bl/6 mice with L-NAME reduced serum NOx by 71%
on day 1 and by 66% on day 3. These levels were similar to
those noted in the eNOS/ group (Fig 1).
The eNOS/ and early L-NAME treatment groups
demonstrated significant toe necrosis by the second day
after induction of ischemia, whereas wild-type mice did not
(Fig 2, A). All three groups demonstrated a significant
reduction of flow to the ischemic hind limb immediately
after femoral artery excision, whereas flow to the contralat-
eral hind limb did not change; consequently, the ischemic/
nonischemic limb flow ratio decreased in all three groups.
This circumstance remained unchanged in all three groups
through day 2. On day 3, however, the wild-type group
demonstrated an increase in flow to the ischemic hind limb,
resulting in an ischemic/nonischemic flow ratio that was
more than twofold greater than that noted in the
eNOS/ or L-NAME groups (Fig 2, B). The ischemic/
nonischemic collateral artery diameter ratio was 45% lower
Fig 1. Serum nitrite (NOx) concentration in wild-type, endothe-
lial nitric oxide synthase (eNOS/) and earlyNG-nitro-L-arginine
methyl ester (L-NAME) treatment groups. The serum NOx level
was lower in the eNOS/ mice than in the wild-type mice.
L-NAME significantly reduced serum NOx levels 1 day after
beginning L-NAME treatment, and the reduction was sustained
throughout the duration of L-NAME treatment.in the eNOS/ group and 55% lower in the early L-Fig 2. Responses of wild-type, endothelial nitric oxide synthase
(eNOS/) and early NG-nitro-L-arginine methyl ester (L-NAME)
treatment groups to hind limb ischemia. A, Effects of femoral artery
excision on hind limb tissue integrity are shown in photographs that are
representative of all animals in each group. The ischemic hind limb is
shown on the left and white arrows in eNOS/ and L-NAME mice
denote evidence of tissue necrosis. B, Laser Doppler perfusion imager
(LDPI) data are shown. Each mouse underwent 3 scans at each time
point, and the ratio of the LDPI signal from the ischemic and nonisch-
emic hind limbwas calculated; the average ratio was used as a single data
point for each mouse. C, Collateral artery diameter on day 3 after the
induction of hind limb ischemia was determined as the average of the
largest arteries identified within 10 randomly selected low-power fields
for eachmouse by a blinded observer. The ratio of the average diameter
in the ischemic thigh to the average diameter in the nonischemic thigh
was determined for eachmouse and used as a single data point.
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and early NG-nitro-L-arginine methyl ester (L-NAME) treatment groups on day 3 after induction of hind limb
ischemia. A, Quantitation of hemangiocytes, defined as cells that colocalized chemokine (C-X-C motif) receptor 4
(CXCR4) and vascular endothelial growth factor receptor (VEGFR) 1, was determined as the average number of
hemangiocytes present in each mouse in 10 randomly selected high-power fields, determined by a blinded observer.
B, In representative photomicrographs (original magnification 200) of hemangiocyte immunostaining, VEGFR1 is
stained green, CXCR4 is stained red, and nuclei are stained blue. A collateral vessel is present in each photomicrograph,
evidenced by the linear cord of blue-stained nuclei. Note the presence of double-stained hemangiocytes clustered along
the collateral artery in the ischemic thigh of the control mouse.C,Confocal microscopy of a collateral artery within the
ischemic thigh of the wild-type group. The left photo is shown at original magnification200. The area delineated by
the white square in the left photo is shown at original magnification 400 in the right photo. Note the presence of a
hemangiocyte in the adventitial area of a collateral artery. This adventitial distribution of hemangiocytes was commonly
observed in the ischemic thigh muscle of wild-type mice, but it was never observed in eNOS/ or early L-NAME
treatment groups.
used
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(Fig 2, C).
The number of CXCR4 VEGFR1 hemangiocytes
within the ischemic thigh muscle was 86% less in the
eNOS/ and early L-NAME treatment groups than in
the wild-type group (Fig 3, A). These cells were clearly
aligned along collateral arteries in the ischemic thigh
musculature in the wild-type group (Fig 3, B). Confo-
cal microscopy revealed that hemangiocytes were pri-
marily present within the adventitia of the collateral
arteries within the ischemic thigh in the wild-type group
(Fig 3, C).
Late adaptive response to hind limb ischemia.
L-NAME treatment in the late adaptive response experi-
ment was initiated on the third day after induction of hind
limb ischemia, after the LDPI measurement was obtained.
Blood flows to the ischemic and nonischemic hind limbs
were similar in the wild-type and late L-NAME treatment
groups through day 7. Beginning on day 14, blood flow to
the ischemic hind limb became significantly greater in the
wild-type group than the late L-NAME group, whereas
flows to the contralateral nonischemic hind limb were
unchanged; accordingly, the ischemic/nonischemic flow
ratios in the L-NAME group were 33% and 44% less than of
Fig 4. Response of wild-type and late NG-nitro-L-argin
ischemia. A, Laser Doppler perfusion imager (LDPI) dat
ratio of the LDPI signal from the ischemic and nonische
single data point for each mouse. B, Collateral artery d
determined as the average of the largest arteries identified
by a blinded observer. The ratio of the average diam
nonischemic thigh was determined for each mouse andthose in the wild-type group on days 14 and 28, respec-tively (Fig 4, A). The ischemic/nonischemic thigh collat-
eral diameter ratio was 60% less in the late L-NAME group
than the wild-type group on day 28 after induction of hind
limb ischemia (Fig 4, B).
The number of CXCR4 VEGFR1 hemangiocytes
present within the ischemic thigh muscles was 56% less in
late L-NAME treatment group than in the wild-type group
on day 28 after induction of hind limb ischemia, whereas
the number of hemangiocytes present within the contralat-
eral nonischemic thigh muscles was similar in both groups
(Fig 5, A). Interestingly, the distribution of these cells was
different than that observed in the early adaptive response
study on day 3 after induction of hind limb ischemia. Thus,
hemangiocytes were present between myofibers at the sites
occupied by capillaries (Fig 5, B). Confocal microscopy
confirmed the pericapillary location of these hemangiocytes
(Fig 5, C).
DISCUSSION
Adaptations within existing collateral arteries occur
after femoral artery occlusion to restore vascular conduc-
tance and, hence, limb blood flow. The early adaptation is
vasodilation, whereas the late adaption is arteriogenesis, the
later being a process of collateral artery remodeling.3 Re-
ethyl ester (L-NAME) treatment groups to hind limb
ch mouse underwent 3 scans at each time point, and the
ind limb was calculated; the average ratio was used as a
er on day 28 after induction of hind limb ischemia was
ch mouse within 10 randomly selected low-power fields
in the ischemic thigh to the average diameter in the
as a single data point.ine m
a. Ea
mic h
iamet
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etersearch has established that eNOS-derived NO mediates
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sponse to ischemia; however, the role of eNOS-derivedNO
in arteriogenesis remains unclear.11,17-21 The present stud-
ies support a role for eNOS-derived NO in both early and
late collateral artery adaptations. In addition, this study
provides the first evidence, to our knowledge, that eNOS is
requisite for recruitment of hemangiocytes, a unique subset
of bone marrow-derived vascular progenitor cells,10,15 to
the ischemic vasculature.
Occlusion of the femoral artery increases the rate of
blood flow through pre-existing, small-diameter collateral
arteries. This circumstance increases wall shear stress in
these vessels, a mechanical stimulus that increases eNOS
expression and activity, the latter through eNOS phosphor-
ylation.5,17 These events significantly enhance NO produc-
tion and induce vasodilation of existing collateral arteries;
new collateral arteries are not created during this process of
arteriogenesis.3,5,17 The present findings are fully consis-
tent with this process, as collateral artery diameter and
perfusion within the ischemic hind limb were less on day 3
after induction of ischemia in the eNOS/ and early
L-NAME treatment groups than in the wild-type group.
It is known that the early postischemic, NO-induced
vasodilation of collateral arteries is short-lived.3,11,18 Shear
stress, the primary stimulus for this event, dissipates during
vasodilation because shear stress is inversely proportional to
the fourth power of the vessel radius.18 This temporary
vasodilation gives way to collateral artery remodeling, or
arteriogenesis, a process that permanently increases net
collateral artery conductance.2,3 Heretofore, it was not
clear if eNOS-derived NO participates in the process of
arteriogenesis. Yu et al19 and Lloyd et al20 demonstrated
reduced postischemic arteriogenesis when eNOS activity
was blocked or eliminated; in contrast, Mees et al11 failed
to demonstrate an effect of eNOS-derived NO beyond 2
weeks after induction of ischemia. The present findings
support a role for NO during arteriogenesis, because col-
lateral artery diameter and blood flow within the ischemic
hind limb were significantly less in the late L-NAME treat-
ment group than in the wild-type group 28 days after the
induction of ischemia. Collectively, our findings indicate
that NO is an active participant in postischemic vascular
adaptation for at least the first month after the induction of
ischemia.
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Fig 5. Presence of hemangiocytes in the thigh muscu
(L-NAME) treatment groups 28 days after induction of h
as cells that colocalized chemokine (C-X-Cmotif) recepto
(VEGFR) 1, was determined as the average number of h
high-power fields, determined by a blinded observer
immunostaining, VEGFR1 is stained green, CXCR4 is st
obtained at 3 days after the induction of hind limb ischem
between myocytes; that is, at the sites of capillaries (or
ischemic thigh of the wild-type group. The left-hand
delineated by the white square in the left photo is shown
presence of hemangiocytes in the pericapillary region.An alternative means to evaluate the role of eNOS in
postischemic arteriogenesis is by enhancing eNOS activity,
a circumstance that might be predicted to increase collat-
eral artery growth and blood flow recovery. This predica-
tion has been confirmed: the administration of adenovirus
vectors encoding eNOS to the ischemic hind limb,21 over-
expression of constitutively active eNOS in the ischemic
hind limb,11 or dietary supplementation with L-arginine17
significantly improved postischemic arteriogenesis. Restitu-
tion of eNOS activity or administration of exogenous NO
in the late L-NAME treatment group could provide
additional support for the experimental hypothesis, if it
restored arteriogenesis. However, coadministration of
L-arginine and an arginine analogue such as L-NAME
under in vivo conditions, or systemic administration
of NO donor agents such as sodium nitroprusside,
S-nitrosoglutathione, or 3-morpholinosydnonimine, could also
generate confounding results because it would not be clear
if these agents reached the ischemic hind limb.
Femoral artery excision establishes an inflammatory state
within the ischemic tissue; monocytic6 and lymphocytic22
infiltration are requisite for postischemic arteriogenesis and
angiogenesis. Activity of the Ca2-independent isoform
of nitric oxide synthase (iNOS) is increased in homoge-
nates of ischemic hind limb muscle prepared 14 days
after induction of ischemia; protein and messenger RNA
expression of iNOS were not determined, nor was the
specific localization of the iNOS enzyme within the
tissue (personal communication, Jinglian Yan, Worces-
ter, Mass, 2009).
The arginine analogue L-NAME interacts with the
arginine binding sites of both eNOS and iNOS and, al-
though then half maximal inhibitory concentration for
L-NAME for each enzyme (3.1M for iNOS, 0.35 M for
eNOS), indicate a tenfold selectivity of eNOS iNOS,24 it
is likely that some L-NAME–induced inhibition of iNOS
occurred in this study. In contemplating a possible role for
iNOS-derived NO in arteriogenesis, consideration must be
given to the site of NO production, as the exceedingly brief
half-life of NO precludes a direct effect at a distance far
removed from its point of origin. Additional studies of iNOS
are warranted, with specific attention to the location and
cellular source of iNOS expression within the ischemic hind
limb; moreover, iNOS inhibition with 1400W, which has
™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
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the putative role of iNOS-derived NO in arteriogenesis.
An important and novel finding from the present ex-
periments is that eNOS-derived NO is requisite for recruit-
ment of hemangiocytes to the site of ischemic injury.
Hemangiocytes, first described by Jin et al,10 represent a
unique subset of bonemarrow-derived progenitor cells that
participate in postischemic vascular repair.10,15 Hemangio-
cytes differ from endothelial progenitor cells based on
surface antigens; thus, hemangiocytes express CXCR4 and
VEGFR1, whereas endothelial progenitor cells express
CD31, CD133, and VEGFR2.7,8 It is well established that
eNOS-derived NO participates in the recruitment of endo-
thelial progenitor cells to the site of ischemic vascular
injury.12-14
The present findings indicate a similar interaction for
hemangiocytes. Specifically, hemangiocytes were evident in
the adventitia of collateral arteries in the wild-type group by
day 3 after induction of hind limb ischemia, whereas these
cells were present only sporadically within the ischemic
thigh when eNOS-derived NO was not present, that is, in
the eNOS/ or early L-NAME treatment groups. Mobi-
lization and homing of CXCR4 hemangiocytes is also
contingent on the chemokine stromal-derived factor-1
(SDF-1),10 and an interaction between eNOS-derived
NO and SDF-1 has been described;13 in this context,
measurement of SDF-1 in the ischemic hind limb of
eNOS/mice and the use of CXCR4 blocking antibodies
in this group represent two potentially useful lines of fur-
ther investigation.
Another novel finding from these experiments is the
change in location of hemangiocytes during the course of
postischemic vascular recovery: on day 3, these cells were
present along collateral arteries, the site anticipated where
these cells would be participating in arteriogenesis, whereas
on day 28, these cells were present in a pericapillary loca-
tion. Angiogenesis, defined as the de novo generation of
new capillaries, is an essential part of postischemic vascular
adaptation.3 The capillary/myofiber ratio, a marker for
angiogenesis, was not measured in this study; however, the
presence of hemangiocytes in the pericapillary regions be-
tween muscle cells might indicate that angiogenesis had
occurred. Moreover, we propose that NO is requisite for
recruitment of hemangiocytes to the per-capillary location,
as evidenced by the significant reduction of pericapillary
hemangiocytes in the late L-NAME treatment group.
Most of the hemangiocytes seen within capillaries exhib-
ited fragmentation of their nuclei, an observation that sug-
gests apoptosis. It has been proposed that progenitor cells
serve a paracrine effect; thus, these cells affect existing vascular
cells, inducing repair and replication, rather than becoming
permanently incorporated into existing vascular tissue.26
Interestingly, gangrene of the toes consistently oc-
curred in eNOS/ and early L-NAME–treated mice by
day 3 after induction of hind limb ischemia but was never
observed in late L-NAME–treated animals. One explana-
tion for this finding is that the delay in initiating L-NAME
treatment until day 3 after ischemia allowed sufficient time forNO-induced recruitment of hemangiocytes to pre-existing
collateral arteries in a manner similar to that observed in the
wild-type group studied on day 3. These cells have the poten-
tial to restructure the ischemic vasculature by direct12-14 and
paracrine24 actions, improving vascular conductance and
hence perfusion. Another explanation is that mice in the
eNOS/ and early L-NAME treatment groups were unable
to generate the immediate eNOS-derived vasodilation of col-
lateral arteries, a circumstance that would lead to a profound
compromise in downstream perfusion.
We recognize two limitations to the interpretation of our
results. First, the technique of femoral artery excision pro-
duces a sudden and very severe level of ischemia, whereas the
disease process of critical limb ischemia in humans develops
over a period of years.1 A more gradual, clinically duplicative
model of femoral arterial occlusion has been described in rats
that causes less inflammation and less tissue necrosis but lower
levels of blood flow recovery than after acute occlusion.16 This
model uses an ameroid constrictor, however, which is too
large for use in the mouse hind limb.
Second, we did not use perfusion fixation at an in situ
pressure during preparation of the thigh muscles before
collateral artery diameter measurement; instead, this tissue
was prepared at an effective pressure of 0 mm Hg. This
approach certainly limited the diameter of collateral arteries at
the time of measurement. The difference in collateral artery
diameter among study groups was quite substantial, however,
and collateral wall thickness did not vary among groups. It is
thus unlikely that the use of perfusion fixation would have
altered the outcome of collateral artery diameter.
CONCLUSIONS
The present findings are relevant to human peripheral
arterial disease (PAD). PAD patients who develop intermit-
tent claudication or critical limb ischemia have been shown
to have endothelial dysfunction characterized by decrea-
sed NO bioavailability.25 This reduced NO bioavailability
likely results in inadequate collateral artery enlargement in
PAD. In addition, reduced NO bioavailability may impede
the efficacy of molecular or chemical therapeutics in PAD.
Clinical trials administering either recombinant VEGF26 or
recombinant fibroblast growth factor-227 to PAD patients
have demonstrated therapeutic efficacy only after 60 to 90
days of treatment. VEGF and recombinant fibroblast
growth factor-2 both exert their effects by upregulation
and activation of eNOS.28,29 The present study indicates
that eNOS-derived NO is requisite for acute adaptation to
severe ischemia to prevent tissue necrosis and for sustained
arteriogenesis. We propose that treatment with agents
known to enhance eNOS activity may prove a useful ad-
junctive therapy in PAD. Only through a complete under-
standing of the specific and temporally distinct eNOS-
related recovery responses can we hope to achieve effective
molecular and cell-based therapies for human patients.
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